Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 6/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188299 | 0.82 | MAPT (0.40) | MAPTALOX15THRBCNR2 | |
| SCHEMBL4196822 | 0.77 | CMA1 (0.36) | MAPTTP53ALOX15THRB | |
| SCHEMBL13854247 | 0.75 | THRB (0.36) | MAPTTP53ALOX15THRB | |
| SCHEMBL13854249 | 0.73 | THRB (0.34) | MAPTALOX15THRB | |
| SCHEMBL4197956 | 0.72 | THRB (0.36) | MAPTTP53ALOX15THRB | |
| SCHEMBL13854243 | 0.71 | THRB (0.36) | MAPTTP53ALOX15THRB | |
| SCHEMBL13854244 | 0.69 | THRB (0.33) | MAPTALOX15THRB | |
| SCHEMBL14498106 | 0.67 | THRB (0.33) | MAPTTP53ALOX15THRB | |
| SCHEMBL4202518 | 0.67 | SMYD3 (0.44) | THRB | |
| SCHEMBL13854237 | 0.67 | THRB (0.35) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130165-A1 | MIF Inhibitors | MIF, MMP12, IL4 | MAPT 4279/4885TP53 2984/4885SIGMAR1 3403/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | MAPT 4512/4885TP53 2550/4885SIGMAR1 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.